GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Ergo Science Corp (GREY:ERGN) » Definitions » Debt-to-EBITDA

Ergo Science (Ergo Science) Debt-to-EBITDA : 9.64 (As of Sep. 2006)


View and export this data going back to . Start your Free Trial

What is Ergo Science Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ergo Science's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2006 was $0.42 Mil. Ergo Science's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2006 was $0.00 Mil. Ergo Science's annualized EBITDA for the quarter that ended in Sep. 2006 was $0.04 Mil. Ergo Science's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2006 was 9.64.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ergo Science's Debt-to-EBITDA or its related term are showing as below:

ERGN's Debt-to-EBITDA is not ranked *
in the Business Services industry.
Industry Median: 1.925
* Ranked among companies with meaningful Debt-to-EBITDA only.

Ergo Science Debt-to-EBITDA Historical Data

The historical data trend for Ergo Science's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ergo Science Debt-to-EBITDA Chart

Ergo Science Annual Data
Trend Dec96 Dec97 Dec98 Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.29 -0.18

Ergo Science Quarterly Data
Dec01 Mar02 Jun02 Sep02 Dec02 Mar03 Jun03 Sep03 Dec03 Mar04 Jun04 Sep04 Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - N/A - -0.13 9.64

Competitive Comparison of Ergo Science's Debt-to-EBITDA

For the Staffing & Employment Services subindustry, Ergo Science's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ergo Science's Debt-to-EBITDA Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Ergo Science's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ergo Science's Debt-to-EBITDA falls into.



Ergo Science Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ergo Science's Debt-to-EBITDA for the fiscal year that ended in Dec. 2005 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.403 + 0) / -2.214
=-0.18

Ergo Science's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2006 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.424 + 0) / 0.044
=9.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2006) EBITDA data.


Ergo Science  (GREY:ERGN) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ergo Science Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ergo Science's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ergo Science (Ergo Science) Business Description

Traded in Other Exchanges
N/A
Address
402 Office Park Drive, Suite 260, Birmingham, AL, USA, 35223
Ergo Science Corp is a United States based workforce injury prevention and treatment provider. It is focused on employee safety and employer risk reduction. The company offers physical abilities tests built from defensible, peer-reviewed research; evidence-based injury prevention and rehabilitation for diversified businesses.
Executives
Citigroup Inc director 388 GREENWICH STREET, NEW YORK NY 10013
Iticorp director 399 PARK AVENUE, NEW YORK NY 10043
Citicorp Banking Corp director ONE PENNS WAY, NEW CASTLE DE 19720
Citigroup Holdings Co director 336 THE STRAND, LONDON ENGLAND
Court Square Capital Ltd director 399 PARK AVE, NEW YORK NY 10043

Ergo Science (Ergo Science) Headlines

No Headlines